These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 21222497)

  • 81. Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis.
    Ren YR; Jin YD; Zhang ZH; Li L; Wu P
    Chin Med J (Engl); 2015 Feb; 128(3):378-83. PubMed ID: 25635435
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
    Prica A; Baldassarre F; Hicks LK; Imrie K; Kouroukis T; Cheung M;
    Clin Oncol (R Coll Radiol); 2017 Jan; 29(1):e13-e28. PubMed ID: 27746042
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Treatment of non-Hodgkin's lymphoma: a look over the past decade.
    Coiffier B
    Clin Lymphoma Myeloma; 2006 Oct; 7 Suppl 1():S7-13. PubMed ID: 17101073
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?
    Ngu H; Takiar R; Phillips T; Okosun J; Sehn LH
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-14. PubMed ID: 35594501
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.
    Vidal L; Gurion R; Shargian L; Dreyling M; Gafter-Gvili A
    Br J Haematol; 2019 Jul; 186(2):234-242. PubMed ID: 30980398
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
    Dhillon S
    Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance.
    Kim HK; Kang W; Sinn DH; Lee JH; Kim WS; Kim SJ
    Korean J Intern Med; 2020 Jan; 35(1):194-204. PubMed ID: 30935195
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
    Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
    J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
    Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
    J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Advancing Therapy For Chronic Lymphocytic Leukemia-the Role Of Rituximab.
    Hillmen P
    Semin Oncol; 2004 Feb; 31 Suppl 2():22-26. PubMed ID: 28140106
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma.
    Claustre G; Boulanger C; Maloisel F; Etienne-Selloum N; Fornecker LM; Durot E; Slimano F; Graff V
    J Cancer Res Clin Oncol; 2023 May; 149(5):1883-1893. PubMed ID: 35789429
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Role of rituximab in first-line treatment of chronic lymphocytic leukemia.
    Bryan J; Borthakur G
    Ther Clin Risk Manag; 2010 Dec; 7():1-11. PubMed ID: 21339937
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Rituximab maintenance therapy of follicular lymphoma in clinical practice.
    Dührsen U; Broszeit-Luft S; Dieing A; Lück A; Porowski P; Reiser M; Schwinger U; Klawitter S; Krumm K; Jentsch-Ullrich K
    Cancer Med; 2018 Jul; 7(7):2903-2912. PubMed ID: 29761908
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.
    Bastos-Oreiro M; Gutierrez A; Cabero A; López J; Villafuerte P; Jiménez-Ubieto A; de Oña R; De la Fuente A; Navarro B; Peñalver J; Martínez P; Alonso C; Infante M; Córdoba R; Perez-Montero B; Pérez de Oteyza J; González de Villambrosio S; Fernández-Caldas P; Del Campo R; García Belmonte D; Diaz-Gálvez J; Salar A; Sancho JM
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610963
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
    Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherril B; Ruiz-Soto R; Kaye JA; Hamadani M
    J Oncol Pharm Pract; 2016 Oct; 22(5):666-78. PubMed ID: 26320127
    [TBL] [Abstract][Full Text] [Related]  

  • 96. RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.
    Lim SH; Linton KM; Collins GP; Dhondt J; Caddy J; Rossiter L; Vadher K; Fines K; Rogers LE; Fernando D; Stanton L; Davies AJ; Johnson PWM; Griffiths G
    Trials; 2018 Nov; 19(1):619. PubMed ID: 30413184
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
    Hochster H; Weller E; Gascoyne RD; Habermann TM; Gordon LI; Ryan T; Zhang L; Colocci N; Frankel S; Horning SJ
    J Clin Oncol; 2009 Apr; 27(10):1607-14. PubMed ID: 19255334
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Hagemeister F
    Drugs; 2010 Feb; 70(3):261-72. PubMed ID: 20166765
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
    Sawas A; Farber CM; Schreeder MT; Khalil MY; Mahadevan D; Deng C; Amengual JE; Nikolinakos PG; Kolesar JM; Kuhn JG; Sportelli P; Miskin HP; O'Connor OA
    Br J Haematol; 2017 Apr; 177(2):243-253. PubMed ID: 28220479
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.